000098423 001__ 98423
000098423 005__ 20210128133202.0
000098423 0248_ $$2sideral$$a122185
000098423 037__ $$aART-2019-122185
000098423 041__ $$aeng
000098423 100__ $$0(orcid)0000-0001-5632-0351$$aMarron, S.E.
000098423 245__ $$aEfficacy, safety and patient reported outcomes (PROS) in adult patients with atopic dermatitis treated with dupilumab at week-52 in usual clinical practice
000098423 260__ $$c2019
000098423 5060_ $$aAccess copy available to the general public$$fUnrestricted
000098423 5203_ $$aP15
Background: Dupilumab, an anti-interleikin-4-receptor-a monoclonal antibody, is a new treatment for atopic dermatitis in adults.
Objective: To evaluate – at week 52 – patient reported outcomes, satisfaction, efficacy and safety, with dupilumab in adult patients with moderate-to-severe atopic dermatitis refractory to the usual treatments previously performed under conditions of usual clinical practice.
Methods: Twelve patients were enrolled. Patients from our hospital, under routine clinical practice, were treated with subcutaneous dupilumab 300 mg every 2 weeks. The outcomes were evaluated at baseline, week 4, 8, 12, 16, 28 , 40 and week 52. The variables evaluated were: itch, difficulty to sleep, previous stressful life events, severity (SCORAD), anxiety and depression symptoms (HADS), quality of life (DLQI, EQ5D3L), satisfaction, adherence to the treatment, efficacy and safety.
Results: At week 52 significant improvement was observed in severity, itch, difficulty to sleep, anxiety and depression symptoms, and quality of life. Satisfaction with dupilumab compared to previous treatments was significantly higher in all aspects assessed. No significant dupilumab-induced laboratory abnormalities were noted, and adverse events were mild and transient.
Conclusions: Dupilumab used under routine clinical practice for 52 weeks improved atopic dermatitis signs and symptoms, with a good safety profile and patient satisfaction.
000098423 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttp://creativecommons.org/licenses/by-nc/3.0/es/
000098423 590__ $$a4.016$$b2019
000098423 591__ $$aDERMATOLOGY$$b7 / 68 = 0.103$$c2019$$dQ1$$eT1
000098423 592__ $$a1.01$$b2019
000098423 593__ $$aMedicine (miscellaneous)$$c2019$$dQ1
000098423 593__ $$aDermatology$$c2019$$dQ1
000098423 655_4 $$ainfo:eu-repo/semantics/conferenceObject$$vinfo:eu-repo/semantics/publishedVersion
000098423 700__ $$aAlcalde-Herrero, V.M.
000098423 700__ $$aGarcía Latasa de de Aranibar, F.J.$$uUniversidad de Zaragoza
000098423 700__ $$aMoncin-Torres, C.A.
000098423 700__ $$aFuentelsaz del Barrio, M.V.
000098423 700__ $$0(orcid)0000-0002-1691-3280$$aAlvarez-Salafranca, M.$$uUniversidad de Zaragoza
000098423 700__ $$0(orcid)0000-0003-1917-6906$$aTomas-Aragones, L.$$uUniversidad de Zaragoza
000098423 7102_ $$14009$$2735$$aUniversidad de Zaragoza$$bDpto. Psicología y Sociología$$cÁrea Psicolog.Evolut.Educac
000098423 7102_ $$11007$$2183$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cÁrea Dermatología
000098423 773__ $$g99, 8 (2019), 751$$pActa derm.-venereol.$$tACTA DERMATO-VENEREOLOGICA$$x0001-5555
000098423 85641 $$uhttps://www.medicaljournals.se/acta/download/10.2340/00015555-3228/$$zTexto completo de la revista
000098423 8564_ $$s88579$$uhttps://zaguan.unizar.es/record/98423/files/texto_completo.pdf$$yVersión publicada
000098423 8564_ $$s4176705$$uhttps://zaguan.unizar.es/record/98423/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000098423 909CO $$ooai:zaguan.unizar.es:98423$$particulos$$pdriver
000098423 951__ $$a2021-01-28-12:42:39
000098423 980__ $$aARTICLE